Lack of a role of glutathione in cellular nonenzymatic activation of BMS-181174, a novel analogue of mitomycin C

Hong Xia, Tina Pinto, Xun Hu, Patrick J. Benson, Howard A. Zaren, Vicram Gupta, Shivendra V. Singh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Recent studies, using a cell-free system, have suggested that thiol- dependent nonenzymatic bioactivation may be responsible for the superior antitumor activity of the mitomycin C analogue BMS-181174 [N-7-[2-(4- nitrophenyldithio)ethyl]mitomycin CI when compared to the parent compound. If operational in tumor cells, this pathway could have enormous clinical implications since tumor cell resistance to a variety of anticancer agents is often associated with increased glutathione (GSH) levels and BMS-181174 may be used to reverse this mechanism of resistance. The present study was undertaken to determine the role of GSH in cellular activation of BMS-181174 using a pair of well-characterized human bladder cancer cells (J82 and SCaBER) as a model. A 20-h pretreatment of J82 and SCaBER cells with a nontoxic concentration of D,L-buthionine-S,R-sulfoximine (BSO) caused about 80-88% reduction in cellular GSH levels. Surprisingly, the sensitivity of both cells to BMS-181174 was increased, not reduced, by BSO-induced GSH depletion. On the other hand, the cytotoxicity of BMS-181174 was significantly reduced in both cells by a 4-h pretreatment with 1 mM GSH. Like BSO, a 4-h pretreatment with another thiol compound (cysteine) resulted in a statistically significant sensitization of both cells to BMS-181174. Cellular GSH levels were not affected in either of the cell lines by pretreatment with GSH or cysteine. In conclusion, the results of the present study argue against a role of GSH in cellular nonenzymatic activation of BMS-181174 in J82 and SCaBER cells.

Original languageEnglish (US)
Pages (from-to)3495-3498
Number of pages4
JournalCancer Research
Volume56
Issue number15
StatePublished - Aug 1 1996

Fingerprint

Mitomycin
Glutathione
Sulfhydryl Compounds
Cysteine
Cell-Free System
N-7-(2-(nitrophenyldithio)ethyl)mitomycin C
Urinary Bladder Neoplasms
Antineoplastic Agents
Neoplasms
Cell Line
buthionine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Xia, H., Pinto, T., Hu, X., Benson, P. J., Zaren, H. A., Gupta, V., & Singh, S. V. (1996). Lack of a role of glutathione in cellular nonenzymatic activation of BMS-181174, a novel analogue of mitomycin C. Cancer Research, 56(15), 3495-3498.

Lack of a role of glutathione in cellular nonenzymatic activation of BMS-181174, a novel analogue of mitomycin C. / Xia, Hong; Pinto, Tina; Hu, Xun; Benson, Patrick J.; Zaren, Howard A.; Gupta, Vicram; Singh, Shivendra V.

In: Cancer Research, Vol. 56, No. 15, 01.08.1996, p. 3495-3498.

Research output: Contribution to journalArticle

Xia, H, Pinto, T, Hu, X, Benson, PJ, Zaren, HA, Gupta, V & Singh, SV 1996, 'Lack of a role of glutathione in cellular nonenzymatic activation of BMS-181174, a novel analogue of mitomycin C', Cancer Research, vol. 56, no. 15, pp. 3495-3498.
Xia H, Pinto T, Hu X, Benson PJ, Zaren HA, Gupta V et al. Lack of a role of glutathione in cellular nonenzymatic activation of BMS-181174, a novel analogue of mitomycin C. Cancer Research. 1996 Aug 1;56(15):3495-3498.
Xia, Hong ; Pinto, Tina ; Hu, Xun ; Benson, Patrick J. ; Zaren, Howard A. ; Gupta, Vicram ; Singh, Shivendra V. / Lack of a role of glutathione in cellular nonenzymatic activation of BMS-181174, a novel analogue of mitomycin C. In: Cancer Research. 1996 ; Vol. 56, No. 15. pp. 3495-3498.
@article{677736df76dd4289a3bb872ba1d6a7cf,
title = "Lack of a role of glutathione in cellular nonenzymatic activation of BMS-181174, a novel analogue of mitomycin C",
abstract = "Recent studies, using a cell-free system, have suggested that thiol- dependent nonenzymatic bioactivation may be responsible for the superior antitumor activity of the mitomycin C analogue BMS-181174 [N-7-[2-(4- nitrophenyldithio)ethyl]mitomycin CI when compared to the parent compound. If operational in tumor cells, this pathway could have enormous clinical implications since tumor cell resistance to a variety of anticancer agents is often associated with increased glutathione (GSH) levels and BMS-181174 may be used to reverse this mechanism of resistance. The present study was undertaken to determine the role of GSH in cellular activation of BMS-181174 using a pair of well-characterized human bladder cancer cells (J82 and SCaBER) as a model. A 20-h pretreatment of J82 and SCaBER cells with a nontoxic concentration of D,L-buthionine-S,R-sulfoximine (BSO) caused about 80-88{\%} reduction in cellular GSH levels. Surprisingly, the sensitivity of both cells to BMS-181174 was increased, not reduced, by BSO-induced GSH depletion. On the other hand, the cytotoxicity of BMS-181174 was significantly reduced in both cells by a 4-h pretreatment with 1 mM GSH. Like BSO, a 4-h pretreatment with another thiol compound (cysteine) resulted in a statistically significant sensitization of both cells to BMS-181174. Cellular GSH levels were not affected in either of the cell lines by pretreatment with GSH or cysteine. In conclusion, the results of the present study argue against a role of GSH in cellular nonenzymatic activation of BMS-181174 in J82 and SCaBER cells.",
author = "Hong Xia and Tina Pinto and Xun Hu and Benson, {Patrick J.} and Zaren, {Howard A.} and Vicram Gupta and Singh, {Shivendra V.}",
year = "1996",
month = "8",
day = "1",
language = "English (US)",
volume = "56",
pages = "3495--3498",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Lack of a role of glutathione in cellular nonenzymatic activation of BMS-181174, a novel analogue of mitomycin C

AU - Xia, Hong

AU - Pinto, Tina

AU - Hu, Xun

AU - Benson, Patrick J.

AU - Zaren, Howard A.

AU - Gupta, Vicram

AU - Singh, Shivendra V.

PY - 1996/8/1

Y1 - 1996/8/1

N2 - Recent studies, using a cell-free system, have suggested that thiol- dependent nonenzymatic bioactivation may be responsible for the superior antitumor activity of the mitomycin C analogue BMS-181174 [N-7-[2-(4- nitrophenyldithio)ethyl]mitomycin CI when compared to the parent compound. If operational in tumor cells, this pathway could have enormous clinical implications since tumor cell resistance to a variety of anticancer agents is often associated with increased glutathione (GSH) levels and BMS-181174 may be used to reverse this mechanism of resistance. The present study was undertaken to determine the role of GSH in cellular activation of BMS-181174 using a pair of well-characterized human bladder cancer cells (J82 and SCaBER) as a model. A 20-h pretreatment of J82 and SCaBER cells with a nontoxic concentration of D,L-buthionine-S,R-sulfoximine (BSO) caused about 80-88% reduction in cellular GSH levels. Surprisingly, the sensitivity of both cells to BMS-181174 was increased, not reduced, by BSO-induced GSH depletion. On the other hand, the cytotoxicity of BMS-181174 was significantly reduced in both cells by a 4-h pretreatment with 1 mM GSH. Like BSO, a 4-h pretreatment with another thiol compound (cysteine) resulted in a statistically significant sensitization of both cells to BMS-181174. Cellular GSH levels were not affected in either of the cell lines by pretreatment with GSH or cysteine. In conclusion, the results of the present study argue against a role of GSH in cellular nonenzymatic activation of BMS-181174 in J82 and SCaBER cells.

AB - Recent studies, using a cell-free system, have suggested that thiol- dependent nonenzymatic bioactivation may be responsible for the superior antitumor activity of the mitomycin C analogue BMS-181174 [N-7-[2-(4- nitrophenyldithio)ethyl]mitomycin CI when compared to the parent compound. If operational in tumor cells, this pathway could have enormous clinical implications since tumor cell resistance to a variety of anticancer agents is often associated with increased glutathione (GSH) levels and BMS-181174 may be used to reverse this mechanism of resistance. The present study was undertaken to determine the role of GSH in cellular activation of BMS-181174 using a pair of well-characterized human bladder cancer cells (J82 and SCaBER) as a model. A 20-h pretreatment of J82 and SCaBER cells with a nontoxic concentration of D,L-buthionine-S,R-sulfoximine (BSO) caused about 80-88% reduction in cellular GSH levels. Surprisingly, the sensitivity of both cells to BMS-181174 was increased, not reduced, by BSO-induced GSH depletion. On the other hand, the cytotoxicity of BMS-181174 was significantly reduced in both cells by a 4-h pretreatment with 1 mM GSH. Like BSO, a 4-h pretreatment with another thiol compound (cysteine) resulted in a statistically significant sensitization of both cells to BMS-181174. Cellular GSH levels were not affected in either of the cell lines by pretreatment with GSH or cysteine. In conclusion, the results of the present study argue against a role of GSH in cellular nonenzymatic activation of BMS-181174 in J82 and SCaBER cells.

UR - http://www.scopus.com/inward/record.url?scp=0029973856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029973856&partnerID=8YFLogxK

M3 - Article

C2 - 8758917

AN - SCOPUS:0029973856

VL - 56

SP - 3495

EP - 3498

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 15

ER -